Adverum Biotechnologies Inc (ADVM)

$4.33 +0.04 (0.93%)
Market Cap 89.24M
Revenue (ttm) 3.60M
Net Income (ttm) -117.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,254.72%
Debt to Equity Ratio 0.00
Volume 120,300
Avg Vol 238,094
Day's Range N/A - N/A
Shares Out 20.80M
Stochastic %K 29%
Beta 0.96
Analysts Strong Sell
Price Target $29.71

Latest News on ADVM

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 6, 2024, 4:05 PM EST - 6 weeks ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2024, 4:05 PM EST - 2 months ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 18, 2024, 1:37 PM EST - 2 months ago

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Nov 15, 2024, 4:05 PM EST - 2 months ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Nov 4, 2024, 4:39 PM EST - 2 months ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Oct 16, 2024, 8:00 AM EDT - 3 months ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Sep 4, 2024, 4:05 PM EDT - 4 months ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 2, 2024, 7:00 AM EDT - 6 months ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Jul 17, 2024, 3:35 PM EDT - 6 months ago

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Jul 17, 2024, 2:45 AM EDT - 6 months ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

May 9, 2024, 4:05 PM EDT - 9 months ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

May 3, 2024, 8:00 AM EDT - 9 months ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Apr 25, 2024, 4:05 PM EDT - 9 months ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Mar 18, 2024, 4:05 PM EDT - 10 months ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:05 PM EST - 11 months ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Feb 8, 2024, 7:00 AM EST - 1 year ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Feb 5, 2024, 7:45 AM EST - 1 year ago

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Feb 1, 2024, 5:30 PM EST - 1 year ago

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Jan 29, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Dec 7, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Nov 28, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Nov 9, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Nov 6, 2023, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Nov 4, 2023, 5:54 PM EDT - 1 year ago

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

Adverum Biotechnologies to Participate in Upcoming Investor Conferences

Sep 21, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming Investor Conferences

Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy

Aug 23, 2023, 2:46 PM EDT - 1 year ago

Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy

Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

Aug 21, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

Jun 12, 2023, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

Adverum Biotechnologies Announces New Executive Leadership Roles

May 25, 2023, 6:30 AM EDT - 1 year ago

Adverum Biotechnologies Announces New Executive Leadership Roles

Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

May 18, 2023, 9:00 AM EDT - 1 year ago

Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

May 18, 2023, 9:00 AM EDT - 1 year ago

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

May 11, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference

May 10, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference

Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD

May 2, 2023, 4:30 PM EDT - 1 year ago

Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD

Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

Apr 23, 2023, 1:00 PM EDT - 1 year ago

Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD

Apr 18, 2023, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD

Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting

Apr 17, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update

Mar 30, 2023, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update

Adverum Biotechnologies to Present at Upcoming Investor Conferences

Feb 27, 2023, 4:05 PM EST - 2 years ago

Adverum Biotechnologies to Present at Upcoming Investor Conferences

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 18, 2023, 4:05 PM EST - 2 years ago

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 4:05 PM EST - 2 years ago

Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)

Nov 4, 2022, 12:08 PM EDT - 2 years ago

Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)

Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting

Oct 27, 2022, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting

Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD

Sep 30, 2022, 4:45 PM EDT - 2 years ago

Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD